Publicly, Joe Biden never wavered. Privately, those close to him that the President would eventually intervene and end the federal prosecutions against his son. Sunday evening’s surprise announcement of a sweeping pardon for Hunter Biden sent Washington ablaze with . Talk turned to what this about-face would mean for the President’s , the impact it might have on the Justice Department’s already battered , and whether President-elect Donald Trump, himself a , would accept the pardon as the final word. It all felt very loud, very urgent—and, to some, very predictable. Yet, when you take a look at Biden’s choice—making use of a power in the Constitution with very few limits—it starts to make some sense. Yes, Biden flip-flopped on a pretty absolute not to exercise the right to spare his son. Yes, it flies in the face of Democrats’ long-standing criticism about Trump, that no one should be regardless of ties to the Oval Office. And, yes, this is going to dog Biden’s final weeks in office in ways that could distract from his urgent work to build a legacy after a half-century in public life. But all those criticisms ignore a bigger truth: Joe Biden faced a trickier decision than whether or not to keep his only living son out of prison. Many will ding it as an entirely selfish move by a guilty father going with his gut. Yet, in a way, this was maybe the most considered decision Biden has made this calendar year—and that includes the jarring in July that he would step aside as the Democratic Party’s nominee. Here are the six factors that explain why Biden signed the roughly 200-word order: For years, Hunter Biden and his work for a Ukrainian energy company has been catnip for conservatives—many of whom still believe that the money paid to Hunter for his on the Burisma board was a bag of cash for the Bidens, with Joe Biden skimming a share from the top. (So much of the GOP case against the Bidens has been and their efforts to Joe Biden fell apart.) With Trump about to be back in charge of the Justice Department and FBI—including an FBI potentially led by an outspoken who has endorsed Trump’s to trample his foes in retribution—there was a quiet fear that the President-elect would make Hunter Biden’s misdeeds a priority—even if Hunter Biden was already serving out a prison sentence. Joe Biden’s signature on an extraordinarily broad pardon rendered those efforts pointless, as no federal charges can be summoned. There is no point disputing this. Most experts that for anyone else facing these charges, the cases would have been likely with an in-and-out plea deal, one that was once on the table but by a Trump-appointed judge for its sweep. The prosecution became even more novel once the Trump-nominated U.S. Attorney for Delaware special counsel for the Hunter Biden case. With protected standing, Special Counsel David Weiss continued down a path that convictions on three federal felony counts for illegally buying a gun and nine guilty pleas on federal tax charges. Hunter Biden was due to be sentenced on the gun conviction on Dec. 12, followed by a Dec. 16 sentencing on the tax evasion plea. If given the maximum penalties—considered unlikely—he would have faced up to 42 years in prison. Yes, Joe Biden flip-flopped with zero apology. Yes, he was running around the world—literally— everyone the justice system worked for both his son and his rival, Trump. Yes, he would take from some of the same folks whose approval Biden has chased for decades. But voters rendered their verdict on Biden’s by-the-books approach when they chose to Trump to power. Heck, Trump repeatedly mass pardons for those involved in the Jan. 6, 2021, attack on Congress. Voters decided that was appealing—or at least not disqualifying—and chose to give Trump the keys again. If Trump seems to think waving the magic wand of legal do-overs comes with zero costs to him, maybe Biden is rightly betting that he enjoys similar leeway. After all, Trump’s first term included freebies for former Illinois Gov. , former NYPD Commissioner , and “ ” . He also employed his leniency power to spare five and advisers, three uniformed service members of , seven former members of Congress—all Republicans—and 10 health care providers in a massive Medicare fraud scheme. Given that recent history, imagine if Hunter Biden’s mid-December sentencing included years in prison—for transgressions that experts say are rarely prosecuted. What would the public reaction have been if Joe Biden, in the final days of his presidency, refused to use a get-out-of-jail-free card for his very own son? Joe Biden spent his half-century in politics insisting that politics had no place in the judicial system, but that belief ran head-first into a competing precept that family stands above all other concerns. The President’s over the death of his son Beau Biden has been the of so much of the Biden family’s decision-making in the last decade, and surely factored into the President’s thinking as he weighed the prospect of even more his grandkids spending time without their own father. It was a politically fraught move, but not an unexpected one. After all, when an Iowan asked Biden about Hunter’s work in Ukraine back in December of 2019, the then-former VP the man “a damned liar” and challenged him to a push-up contest. Joe Biden followed-up with a to keep his own house in order if elected. And not for nothing, Hunter Biden has been incredibly open about his with addiction, and has seemingly around his life in the years after some admittedly poor choices. A lengthy jail term would do little to teach Hunter Biden any lessons he hasn’t already internalized. That argument appeared to help Joe Biden get to yes. The pardon power is absolute and the President’s alone. There’s no sign off needed from Congress and no one in his administration has any real authority to stop him. That’s why, when Biden said “I will not pardon him” on June 13, some were skeptical. A pardon was always an option, no matter how much his aides and otherwise on All Things Hunt. How else to explain why Joe Biden Hunter Biden to a state dinner just days after the younger Biden cut a doomed deal with federal prosecutors, led by an Attorney General attending the same event? Despite Hunter Biden’s ghosts, he still has sway inside his father’s inner circle as the eldest living child of a once-imagined political . The White House released the news late Sunday, just as Biden was about to hop on a flight heading out on his final foreign trip as President. That puts the President out of Washington until Thursday with no formal press conference on the books, a strategy that follows a South America trip last month that came with a similar media . That leaves a whole lot of time to fill in a Washington subsumed by this apparent violation of Biden’s vow not to do what he just did. And, aboard the presidential flight on Air Force One, the White House’s top spokeswoman on the reversal. And on Monday, as she welcomed National Guard members to the White House to tour the holiday decorations, First Lady Jill Biden got pelted with a question about the pardon. "Of course I support the pardon of my son," Dr. Biden said in the White House’s State Dining Room. On top of that, Washington faces its seemingly auto-renewal gift of a holiday-themed spending deadline; this year, Congress has until Dec. 20 to kick the can down the road, and there’s a whole lot of just how far into Trump’s second term they should be looking toward. Put simply: the pardon is not going to stay front of mind for most Americans, and Trump is likely to find a way to hijack the public discourse as Team Joe runs down the clock.
I'm A Celeb star fumes 'not up for a trial this time of night' as camp thrown into chaosRevolutionizing Gaming? Meet the Game-Changer: Vul StockFianna Fail and Fine Gael eye independent TDs as option to secure Dail majorityLong-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
None
LAUSANNE , Switzerland , Dec. 2, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 34,900 of the Company's common shares to three new employees on December 2, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland , and has operations in London and New Jersey . For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn . ZYNLONTA ® is a registered trademark of ADC Therapeutics SA. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA ® revenue in the United States ; the ability of our partners to commercialize ZYNLONTA ® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA ® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, ADCT 602 as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS: Investors Marcy Graham ADC Therapeutics Marcy.Graham@adctherapeutics.com +1 650-667-6450 Media Nicole Riley ADC Therapeutics Nicole.Riley@adctherapeutics.com +1 862-926-9040 View original content to download multimedia: https://www.prnewswire.com/news-releases/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-302320100.html SOURCE ADC Therapeutics SATitans QB Mason Rudolph gets another chance at starting, this time against the Jags
The Boston Celtics look good value to defend their title, in large part to the play of Jayson Tatum. A consensus top-five player in the league who is coming off his first NBA championship and Olympic gold medal over the summer, the Celtics star has positioned his squad to a 16-4 start, good for second in the East. However, the last couple of months weren't as smooth sailing for Tatum as everyone would like to believe. During the Olympics , Tatum received very little to no playing time throughout Team USA's run to the gold. But Celtics teammate and Team USA teammate Jrue Holiday revealed on the Podcast P with Paul George that Tatum could not have handled his situation any better. “JT, the way he handled it, he handled it like a professional," Holiday said. “He never brought it in the locker room, he never brought it to us like, yeah, we talked about it and all that, but it was never like it was an issue.” Holiday sang Tatum's maturity and professionalism, while also being puzzled at the same time as to why Team USA's head coach, Steve Kerr, chose to restrict Tatum's playing time. “Was it weird? Yeah, it’s Jayson Tatum ,” Holiday said. “What do you mean? He’s a top five player in the league, just won a championship, one of the best players in the playoffs and in the Finals. “When it was happening, you felt for him. You could see that he was upset, he wanted to play. "But he wasn't pouting, I can tell you that. He would get in the gym. It's not like he stopped working. "He was the one seriously trying to be like, all right, well, I'm gonna stay ready whenever my numbers called." George was also impressed with how Tatum handled the whole situation. "I did think he handled that amazingly," George said. "He handled it like a professional. Shoutout JT, that was dope." Not often does a player coming off a championship run have to take a backseat at the Olympics. But that is exactly what Tatum did, as the team was centered on the presumed last run for LeBron James , Steph Curry and Kevin Durant . It was the proverbial swan song for the big three and their Team USA careers. They didn't lose a single game, while all three superstars had their individual moments, most notably Curry in the semifinals against Serbia, and then again in the gold medal game against France. Tatum's limited playing time in Paris clearly hasn't impacted his start to the season as he is currently averaging 28.9 points per game to go along with 8.5 rebounds and 5.7 assists. In other words, he's once again playing at an MVP-level. As Holiday noted, Tatum handled it all with class, and in turn, it looks as though it has fueled him to begin the season. That's a scary sign for the rest of the league.Titans QB Mason Rudolph gets another chance at starting, this time against the Jags